Sugarloaf Wealth Management LLC Lowers Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sugarloaf Wealth Management LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 331 shares of the medical research company’s stock after selling 29 shares during the quarter. Sugarloaf Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $172,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. LPL Financial LLC lifted its position in Thermo Fisher Scientific by 4.6% in the second quarter. LPL Financial LLC now owns 217,770 shares of the medical research company’s stock valued at $120,427,000 after purchasing an additional 9,578 shares during the period. Johnson Investment Counsel Inc. lifted its holdings in Thermo Fisher Scientific by 3.4% in the second quarter. Johnson Investment Counsel Inc. now owns 9,359 shares of the medical research company’s stock valued at $5,176,000 after acquiring an additional 309 shares during the period. Oppenheimer & Co. Inc. boosted its position in shares of Thermo Fisher Scientific by 0.5% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 31,433 shares of the medical research company’s stock worth $17,382,000 after purchasing an additional 144 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Thermo Fisher Scientific by 6.9% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 819,893 shares of the medical research company’s stock valued at $450,892,000 after purchasing an additional 52,675 shares in the last quarter. Finally, Meeder Advisory Services Inc. boosted its holdings in Thermo Fisher Scientific by 37.1% during the second quarter. Meeder Advisory Services Inc. now owns 7,410 shares of the medical research company’s stock worth $4,098,000 after buying an additional 2,005 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 0.4 %

Shares of Thermo Fisher Scientific stock opened at $542.97 on Friday. The company has a fifty day moving average price of $529.91 and a 200 day moving average price of $567.91. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The stock has a market cap of $207.69 billion, a price-to-earnings ratio of 34.04, a price-to-earnings-growth ratio of 3.54 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period last year, the business posted $5.69 EPS. The company’s revenue was up .2% on a year-over-year basis. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share buyback program on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on TMO shares. JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Bernstein Bank raised their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research report on Tuesday, October 22nd. Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 price objective on the stock. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $650.52.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock worth $25,954,465 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.